The hypermethylation in promoter region of CDH13 was frequently observed in lung cancer, and proposed to correlate to drug sensitivity and poorer prognosis (Kontic et al., 2012; Toyooka et al., 2006; Zhai & Li, 2014; Zhong et al., 2015). Here, CDH13 is linked to lung carcinoma.